From Wikipedia, the free encyclopedia
|(what is this?)|
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009[update], it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|